Phase 3 N=18 Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis
Chronic Sinusitis · Polyposis
Primary: Olfaction — 20.2; 19.8 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=122 Prevention of Preterm Birth With a Pessary in Singleton Gestations
Preterm Birth · Short Cervix
Primary: Number of Subjects Experiencing Preterm Birth — 26; 23 Participants
Phase 3 N=288 Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Relative Change From Baseline in Duration of Morning Stiffness at Week 12 — -22.7; -0.4 percent change
N/A N=46 Prevention of Preterm Birth With a Pessary in Twin Gestations
Premature Birth · Short Cervix
Primary: Number of Participants With Preterm Delivery — 9; 8 Participants
N/A N=26 Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic
Asthma
Primary: Airway Symptom Scores Experienced by Subjects During the 1st 4 Days of the Infection — 8.72; 2.77 units on a scale — p=0.049
N/A N=1,860 Prospective Cohort for the Evaluation of Biomarkers Following HCT (BMT CTN 1202)
Allogeneic Hematopoietic Stem Cell Transplantation
Primary: Number of Participants Providing Biologic Samples — 1709 Participants
Phase 2 N=364 A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Primary: Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 — 0; 0; 0; 0 Participants
N/A N=9 Surgical Treatment of Pelvic Joint Instability in Patients With Severe Pelvic Girdle Pain After Pregnancy and Trauma
Pelvic Joint Instability · Pelvic Pain
Primary: Oswestry Disability Index (ODI) — 54; 37 units on a scale
Phase 2 N=74 Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Cholangiocarcinoma
Primary: Progression-Free Survival (PFS) Rate at 6 Months (Proportion of Participants Alive and Progression-Free at 6 Months) — 0.605 proportion of participants
Phase 3 N=1,522 VA Augmentation and Switching Treatments for Improving Depression Outcomes
Major Depressive Disorder
Primary: Rate of Protocol Remission of Symptoms of Major Depressive Disorder — 114; 136; 146 Participants — p=0.076
Phase 4 N=44 Effect of DPP4 Inhibition on Growth Hormone Secretion
Obesity
Primary: Aim 1: Stimulated Peak Growth Hormone Level — 5.2; 3.1; 1.9; 2.0 ng/ml
N/A N=120 Colonoscope Passive Bending Function
Colitis · Adenoma · Carcinoma
Primary: Patient Assessment of Pain Experienced During Colonoscopy — 19; 10 participants
Phase 4 N=437 Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
Diabetes · Type 2 Diabetes Mellitus
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.66; -1.52 Percentage (%) of HbA1c — p=0.2601
N/A N=242 Alternative Approaches for Nausea Control
Nausea
Primary: Patient Report Nausea Diary — 3.87; 3.55; 3.52 units on a scale — p=.05
Phase 2 N=17 Prolonged Exposure and Oxytocin
PTSD
Primary: PTSD Symptom Severity — 13.00; 17.71 scores on a scale